Ohad Hammer from Pontifax has joined the Eyevensys Board. Eyevensys will use the funds raised to secure the clinical development of its lead product candidate EYS606 that will enter into an open-label Phase Ib study in premier Ophthalmological Centres in France and in the UK by the end of 2016 as a potential treatment for Non-Infectious Uveitis (NIU). This study is expected to be completed towards the end of 2017. EYS606 is the first non-viral product that has the potential to treat NIU patients for up to 6 to 12 months following one injection. The treatment uses the Company’s proprietary electro-transfection injection system (ETIS) to deliver plasmids encoding for the production of anti-TNF in the ciliary muscle of the eye. TNF is a cytokine that has been shown to play a pivotal role in mediating intraocular inflammation in NIU. In January 2016, EYS606 has been granted an Orphan designation by EMA for the treatment of NIU. Raffy Kazandjian, CEO of Eyevensys, said: “We are grateful that Pontifax, a leading health-care dedicated venture fund, alongside our existing investors, share our excitement about the potential of EyeCET’s technology to deliver long-lasting treatment to address a wide range of ophthalmic diseases. This extension funding supports our clinical strategy on EYS606 and will also allow us to start to unlock the potential of our pre-clinical pipeline.” Ohad Hammer, of Pontifax Venture Capital, said: “Delivering drugs to the eye is one of the major challenges in the ophthalmology area.
For the original version including any supplementary images or video, visit http://www.prnewswire.com/news-releases/eyevensys-announces-series-a-extension-bringing-total-capital-raised-to-9-million-593503361.html
The.ollowing.ay help your symptoms wear dark glasses if your eye becomes sensitive to light place a warm flannel over the eye to soothe it relieve pain by taking painkillers, such as ibuprofen Page last reviewed: 27/01/2015 Uveitis means inflammation of the part of the eye called the urea. B J Opthalmol. 2013;972:134-8. no dataSuccessful treatment of active uveitis increases T-regulatory cells in the eye, which likely contributes to disease regression. 27 In some cases an injection of posterior sub tenon triamcinolone acetate may also be given to reduce the swelling of the eye. 28 Antimetabolite medications, such as methotrexate are often used for recalcitrant or more aggressive cases of uveitis. Ophthalmic burg Lasers Imaging Retina. 2013 Jan-Feb. 441:25-7. Posterior uveitis – A rare form of the disorder that affects the back part of the eye, the choroid, and can affect the retina and/or optic nerve. People who get this therapy usually have severe, long-lasting cases of uveitis, often in just one eye. Other potential causes include fungus, bacteria, parasite, inflammatory disease affecting other parts of the body, or injury to the eye. The dark hole in the middle of the iris is the pupil. Medline . Am J Ophthalmol. 2006;1411:157-66. The following are treatment options for each type of uveitis: Treatment for anterior uveitis, or iritis, includes dark glasses, eye drops to dilate the pupil and reduce pain, and steroid eye drops to reduce inflammation or irritation. Uveitis Also known as Iridocyclitis Hypopyon in anterior uveitis, seen as yellowish exudate in lower part of anterior chamber of eye Classification and external resources’ Uveitis is the inflammation of the urea, the pigmented layer that lies between the inner retina and the outer fibrous layer composed of the sclera and cornea . Uveitis is caused by inflammatory responses inside the eye. A corticosteroid medication reduces inflammation and pain of the eye and helps to improve symptoms.
The iris is the coloured part of the front of the eye. The middle part of the eye includes the pars plan, which is the part of the eye between the iris and the choroid. January 2011. Anterior uveitis – The most common form of uveitis accounting for 40-70% of cases, it affects the iris and its surrounding tissue, the biliary body. Panuveitis uveitis – a term used when all three major parts of the eye are affected by inflammation. Carr Odin Allergy Cain Immunol. 2014 Oct. 14 5:485-9. March 2004. no dataIt is made up of three structures: The iris — The donut-shaped part that gives the eye its colon The choroid — A membrane full of tiny blood vessels that lines the eye The biliary body — A thick ring of tissue that helps control the shape of the lens, and is attached to the iris and to the front portion of the choroid Various terms are used for the condition, depending on the part of the urea affected. Inflammation of the urea can lead to loss of vision.